Bristol-Myers' Daklinza, in combo with other agents, shows cure rates as high as 100% in HCV-3 patients in late-stage study

• Results from a Phase 3 clinical trial, ALLY-3+, evaluating the combination of Bristol-Myers Squibb's (NYSE:BMY +0.3%) Daklinza (daclatasvir), Gilead's (GILD -0.5%) Sovaldi (sofosbuvir) and ribavirin (RBV) in HCV-3 patients with advanced fibrosis or cirrhosis show cure rates as high as 100% after 12 - 16 weeks. The data will be presented today at The Liver Meeting in San Francisco.
• 100% of the patients in the advanced fibrosis cohort achieved SVR12 in both the 12- and 16-week arms. In the cirrhosis cohort, the cure rates in the 12- and 16-week arms were 83% and 89%, respectively.
• Daklinza, approved by the FDA in July, is an NS5A inhibitor indicated for the treatment of HCV-3-positive adults (in combination with Sovaldi).